Avidity Biosciences, Inc (RNAM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Avidity Biosciences, Inc (RNAM) has a cash flow conversion efficiency ratio of -0.101x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-169.77 Million) by net assets ($1.69 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Avidity Biosciences, Inc balance sheet independence to measure how much of total assets are equity-financed.
Avidity Biosciences, Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Avidity Biosciences, Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how aggressively does Avidity Biosciences, Inc reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Avidity Biosciences, Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Avidity Biosciences, Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
REXEL S.A. ADR EO 5
F:E7V0
|
N/A |
|
Mankind Pharma Ltd
NSE:MANKIND
|
0.014x |
|
Formosa Plastics Corp
TW:1301
|
0.025x |
|
Realtek Semiconductor Corp
TW:2379
|
0.109x |
|
VAT GROUP AG UNSP.ADR 10
F:19V0
|
N/A |
|
Advanced Energy Industries Inc
NASDAQ:AEIS
|
-0.004x |
|
CACI International Inc
NYSE:CACI
|
0.043x |
|
SPX Corp
NYSE:SPXC
|
0.085x |
Annual Cash Flow Conversion Efficiency for Avidity Biosciences, Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Avidity Biosciences, Inc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see Avidity Biosciences, Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.69 Billion | $-650.44 Million | -0.385x | -82.43% |
| 2024-12-31 | $1.42 Billion | $-300.87 Million | -0.211x | +11.20% |
| 2023-12-31 | $500.76 Million | $-119.06 Million | -0.238x | -0.86% |
| 2022-12-31 | $578.08 Million | $-136.27 Million | -0.236x | +5.17% |
| 2021-12-31 | $381.43 Million | $-94.81 Million | -0.249x | -105.08% |
| 2020-12-31 | $306.22 Million | $-37.12 Million | -0.121x | -218.15% |
| 2019-12-31 | $-65.36 Million | $2.49 Million | -0.038x | -116.23% |
| 2018-12-31 | $-41.13 Million | $-9.65 Million | 0.235x | -- |
About Avidity Biosciences, Inc
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs). Its AOC platform is designed to combine the specificity of monoclonal antibodies with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics. The company's pipeline has three programs in… Read more